Paliperidone palmitate

Drug Profile

Paliperidone palmitate

Alternative Names: Invega Sustenna; Invega Trinza; Paliperidone palmitate long-acting injection; R0-92670; RO-92670; Sustenna; Trevicta; Xeplion

Latest Information Update: 16 Sep 2016

At a glance

  • Originator Johnson & Johnson
  • Developer Janssen Pharmaceutical KK; Johnson & Johnson; Xian-Janssen
  • Class 2 ring heterocyclic compounds; Antipsychotics; Fluorobenzenes; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Schizoaffective disorder; Schizophrenia

Most Recent Events

  • 14 Sep 2016 Scottish Medicines Consortium (SMC) accepts paliperidone palmitate for the treatment of Schizophrenia (In adults)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Schizophrenia in Croatia (IM, Controlled release)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Schizophrenia in Israel (IM, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.


Drug Name Biomarker Name Biomarker Function
Paliperidone palmitate A1C Outcome Measure, Safety
Adiponectin Outcome Measure, Safety
Alkaline phosphatase not specified
angiotensin II receptor, type 2 Outcome Measure
BDNF Outcome Measure
carnitine palmitoyltransferase 1A (liver) Outcome Measure
COMT Outcome Measure
CYP2D6 Outcome Measure
CYP3A4 not specified
CYP3A5 Outcome Measure
dopamine receptor D2 Outcome Measure
DRD3 Outcome Measure
ER alpha Exclusion, Inclusion, Outcome Measure, Safety
FSH Outcome Measure
HTR2C Outcome Measure
Leptin Outcome Measure, Safety
MDR1 Outcome Measure
NFkB Outcome Measure
Osteocalcin Outcome Measure
Prolactin Outcome Measure, Safety
UDP glucuronosyltransferase 1 family, polypeptide A6 not specified
UGT1A1 not specified
WW domain containing oxidoreductase Exclusion, Inclusion, Outcome Measure
For more detail, check out BiomarkerBase: the leading source of information about biomarkers used in drug development and diagnostic tests, tracking over 78753 biomarker uses worldwide by over 830 companies
Back to top